Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith M Regan

Showing results (81-90 of 259) with videos related to

Pageof 26
Sort By:
Psycho-Oncology|January 25, 2007
Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancerAlice B Kornblith, Mark Powell, Meredith M Regan, et al.
BJU International|May 19, 2010
Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancerMiyako Abe, Wanling Xie, Meredith M Regan, et al.
Cancer|October 19, 2011
Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention TrialStephen B Williams, Simpa Salami, Meredith M Regan, et al.
Breast Cancer Research and Treatment|September 6, 2011
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopauseJacquie Chirgwin, Zhuoxin Sun, Ian Smith, et al.
Clinical and Diagnostic Laboratory Immunology|September 11, 2004
Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is alteredMunir M Zaman, Andres Gelrud, Omer Junaidi, et al.
JNCI Cancer Spectrum|July 31, 2019
A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analysesWanling Xie, Susan Halabi, Jayne F Tierney, et al.
Practical Radiation Oncology|June 25, 2018
Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CPStephen A Mihalcik, Jonathan J Chipman, Martin G Sanda, et al.
Urology|February 22, 2019
Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate CancerDavid J Einstein, Dattatraya Patil, Jonathan Chipman, et al.
Immunotherapy|December 20, 2018
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanomaAhmad Tarhini, David McDermott, Apoorva Ambavane, et al.
BJU International|January 11, 2008
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancerMari Nakabayashi, Oliver Sartor, Susanna Jacobus, et al.
Pageof 26

Showing results (81-90 of 259) with videos related to

Sort By:
Pageof 26
Psycho-Oncology|January 25, 2007
Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancerAlice B Kornblith, Mark Powell, Meredith M Regan, et al.
BJU International|May 19, 2010
Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancerMiyako Abe, Wanling Xie, Meredith M Regan, et al.
Cancer|October 19, 2011
Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention TrialStephen B Williams, Simpa Salami, Meredith M Regan, et al.
Breast Cancer Research and Treatment|September 6, 2011
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopauseJacquie Chirgwin, Zhuoxin Sun, Ian Smith, et al.
Clinical and Diagnostic Laboratory Immunology|September 11, 2004
Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is alteredMunir M Zaman, Andres Gelrud, Omer Junaidi, et al.
JNCI Cancer Spectrum|July 31, 2019
A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analysesWanling Xie, Susan Halabi, Jayne F Tierney, et al.
Practical Radiation Oncology|June 25, 2018
Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CPStephen A Mihalcik, Jonathan J Chipman, Martin G Sanda, et al.
Urology|February 22, 2019
Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate CancerDavid J Einstein, Dattatraya Patil, Jonathan Chipman, et al.
Immunotherapy|December 20, 2018
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanomaAhmad Tarhini, David McDermott, Apoorva Ambavane, et al.
BJU International|January 11, 2008
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancerMari Nakabayashi, Oliver Sartor, Susanna Jacobus, et al.
Pageof 26